Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (Diluted Average) (2021 - 2023)

Gyre Therapeutics has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $38.0 million for Q3 2023.

  • Quarterly Shares Outstanding (Diluted Average) rose 20.62% to $38.0 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $38.0 million through Sep 2023, up 20.62% year-over-year, with the annual reading at $31.5 million for FY2022, 2.95% up from the prior year.
  • Shares Outstanding (Diluted Average) was $38.0 million for Q3 2023 at Gyre Therapeutics, up from $37.8 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $38.0 million in Q1 2023 and troughed at $29.9 million in Q2 2021.
  • The 3-year median for Shares Outstanding (Diluted Average) is $31.5 million (2022), against an average of $33.1 million.
  • Year-over-year, Shares Outstanding (Diluted Average) increased 2.95% in 2022 and then increased 20.75% in 2023.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $30.6 million in 2021, then increased by 2.95% to $31.5 million in 2022, then rose by 20.39% to $38.0 million in 2023.
  • Per Business Quant, the three most recent readings for GYRE's Shares Outstanding (Diluted Average) are $38.0 million (Q3 2023), $37.8 million (Q2 2023), and $38.0 million (Q1 2023).